secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001193125-24-279021
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian's veligrotug meets all primary & secondary endpoints in Phase 3 THRIVE-2 chronic TED trial
--------------------------------------------------------------------------------

- Proptosis responder rate 56% vs 8% placebo (48% adj, p<0.0001); 2.34mm mean reduction vs 0.46mm.
- Diplopia response 56% vs 25% (p=0.0006); complete resolution 32% vs 14% (p=0.0152) in chronic patients.
- 54% of veligrotug patients achieved CAS 0 or 1 vs 24% placebo (p=0.006); overall responder rate 56% vs 7%.
- Veligrotug well-tolerated; 94% completed treatment; 9.6% placebo-adjusted rate of hearing impairment.
- BLA submission on track for H2 2025; $753M cash on hand provides runway into H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/0001193125-24-279021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-279021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer